What is Forbion?
Established in 2000 and operating independently since 2006, Forbion has evolved into a cornerstone of the life sciences investment community. The firm specializes in sourcing and guiding biopharmaceutical companies through the complex lifecycle of clinical development. Their investment thesis is multifaceted, spanning early-stage therapeutic breakthroughs to mature drug development programs. Furthermore, the firm has diversified its portfolio through its BioEconomy strategy, which targets sustainable advancements in agriculture, food systems, and environmental materials. As a signatory to the United Nations Principles for Responsible Investment, Forbion integrates rigorous ESG standards into its operational framework, ensuring that its capital deployment drives both financial returns and positive societal impact.
How much funding has Forbion raised?
Forbion has raised a total of $2.2B across 1 funding round:
Unspecified
$2.2B
Unspecified (2024): $2.2B, investors not publicly disclosed
Key Investors in Forbion
Forbion
A specialized life sciences investment firm focused on building and scaling biotech and biopharmaceutical companies from early-stage development to clinical maturity.
BioGeneration Ventures
A strategic partner firm that collaborates with Forbion to identify and support high-potential seed and early-stage biotechnology ventures.
Institutional Partners
Undisclosed institutional investors participating in the funding round to support the expansion of Forbion's global life sciences and BioEconomy strategies.
What's next for Forbion?
With the recent influx of $2.2B, Forbion is well-positioned to accelerate its strategic initiatives in the life sciences sector. The firm is expected to deepen its focus on high-potential therapeutic assets while expanding its BioEconomy footprint to address global sustainability challenges. By leveraging its joint venture with BioGeneration Ventures, Forbion will likely continue to identify and nurture early-stage ventures that require both capital and deep technical expertise. As the firm navigates the current macroeconomic environment, its focus will remain on building resilient, high-growth companies that define the future of human health and sustainable biotechnology.
See full Forbion company page
